Sono-Photodynamic therapy (SPDT) utilizing ultrasound and light has been demonstrated that this novel approach can lower dosage resulting in reduction of the potential side effects caused by sensitizers. Recently, a new formulation of rose bengal (RB) as an intralesional injection has completed clinical trials phase II for PDT treatment of melanoma cancer. However, the inherent unfavorable pharmacological properties of RB hindered its extensive clinical development. With the aim to identify new RB derivatives (RBDs) with enhanced photodynamic and sonodynamic anticancer efficiency, a series of amphiphilic RBDs have been designed, synthesized and biological characterized. Among them, RBD4 significantly improved cellular uptake and enhanced intracellular ROS generation efficiency upon light and ultrasound irradiation, resulting in dramatically improved anticancer potency. Notably, RBD4 has a relative potency similar to sinoporphyrin sodium (DVDMS), indicating its further potential application for SPDT.

利用超声波和光的声光动力学疗法（SPDT）已被证明，这种新颖的方法可以降低剂量，从而减少由敏化剂引起的潜在副作用。最近，一种新的玫瑰孟加拉（RB）病灶内注射制剂已完成用于PDT治疗黑素瘤癌症的II期临床试验。然而，RB固有的不利药理特性阻碍了其广泛的临床开发。为了鉴定具有增强的光动力学和声动力学抗癌效率的新的RB衍生物（RBD），已经设计，合成和生物学表征了一系列两亲RBD。其中，RBD4显着提高了光和超声照射后细胞的摄取并增强了细胞内ROS的产生效率，从而显着提高了抗癌效力。值得注意的是，RBD4的相对效价与卟啉钠（DVDMS）相似，表明其在SPDT中的进一步潜在应用。